STOCK TITAN

Silo Pharma, Inc. - SILO STOCK NEWS

Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.

Silo Pharma, Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company committed to merging traditional therapeutics with psychedelic research to address a variety of underserved conditions. The company's focus spans post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer's disease, Parkinson's disease, and other rare neurological disorders.

Silo's mission is to identify and license transformative assets, funding cutting-edge research to enhance patient well-being and advance the healthcare industry. Recent achievements include the filing of a provisional patent for SP-26, a ketamine-based implant for chronic pain management, and the exclusive licensing of SPC-15 from Columbia University, a novel intranasal treatment for PTSD and anxiety.

Core Business and Projects

  • SPC-15: An intranasal treatment targeting PTSD and stress-induced anxiety disorders. Silo has exercised its option to license SPC-15 from Columbia University, with preclinical studies showing promising results.
  • SP-26: A time-release, ketamine-loaded implant aimed at fibromyalgia and chronic pain relief. The implant has shown positive results in pre-clinical studies and is expected to be the first at-home approved ketamine-based therapeutic if it passes clinical trials.
  • SPC-14: An intranasal compound for the treatment of Alzheimer's disease, showing potential in preclinical studies for improving cognitive function and stress reduction.
  • SPU-16: A CNS-homing peptide targeting multiple sclerosis (MS), developed in collaboration with the University of Maryland, Baltimore.

Silo's innovative approach combines traditional therapies with psychedelic treatments, aiming to develop novel formulations and drug delivery systems. The company's robust pipeline and strategic partnerships with leading medical universities position Silo at the forefront of biopharmaceutical advancements.

Financial Condition and Partnerships

Silo Pharma collaborates extensively with Columbia University and the University of Maryland, Baltimore, providing essential financial resources to advance their research from the clinical stage to commercialization. The company is financially positioned to support ongoing and future projects that could significantly impact the medical and psychedelic treatment landscape.

For more information, visit www.silopharma.com and connect on social media at LinkedIn, X, and Facebook.

Rhea-AI Summary
Silo Pharma plans to submit an IND application for SPC-15 to the FDA in Q1 2024, pending positive results from in vitro lab tests on its selected delivery mechanism.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Silo Pharma, Inc. (SILO) has announced a partnership with Clarivate™ to manage its expanding intellectual property (IP) portfolio. The agreement includes the monitoring, maintenance, and strategic expansion of the Company's IP assets and technology rights, aiming to support pipeline development and reinforce protection for novel assets. Silo Pharma focuses on merging traditional therapeutics with psychedelic research and has acquired IP and technology rights through collaborations with leading universities and researchers. The company currently holds 3 issued and provisional patents, with additional patent applications pending. Year-to-date, Silo Pharma has been awarded 3 new patents and one patent extension, supporting its planned Investigational New Drug (IND) package submission to FDA for SP-26 and the use of central nervous system (CNS) homing peptides to treat Alzheimer's disease and dementia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
none
-
Rhea-AI Summary
Silo Pharma advances formulation development for therapeutic drug SPC-15, in discussions with potential delivery partners
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
none
-
Rhea-AI Summary
Silo Pharma, Inc. has been granted a new patent by the USPTO for their drug SPU-21, a peptide-guided anti-arthritis drug. The patent expands the company's intellectual property and technology rights portfolio, allowing them to selectively target inflamed synovial tissue. The drug has shown promise in inhibiting arthritic progression in preclinical animal models. Silo Pharma plans to use the drug for the development of fusion imaging molecules and nanoparticles to study arthritic pathogenesis. The market for rheumatoid arthritis drugs in the US is expected to reach $63 billion by 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
-
Rhea-AI Summary
Silo Pharma announces research and development agreement for ketamine implant to treat fibromyalgia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
none
-
Rhea-AI Summary
Silo Pharma, Inc. has been granted a new patent by the USPTO for biomarkers used to determine the efficacy of their drug SPC-15 in treating stress-induced affective disorders. The patent expands the claims of the original patent and adds to the company's intellectual property.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
none
Rhea-AI Summary

Silo Pharma, a biopharmaceutical company focusing on psychedelic research, announced that James Kuo, M.D., will present at the 3rd Annual Psychedelic Therapeutics and Drug Development Conference on May 15-16, 2023, in Burlingame, CA. Dr. Kuo's presentation, titled ‘The Ketamine Endgame,’ will explore the potential of ketamine for treating conditions like treatment-resistant depression, anxiety, and pain. Three of the company's drug candidates utilize ketamine: SP-26 for fibromyalgia, SPC-14 for Alzheimer's-related dementia, and SPC-15 for stress and PTSD. The conference aims to discuss challenges and advancements in psychedelic research for various health conditions including depression, PTSD, and pain management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.74%
Tags
conferences

FAQ

What is the current stock price of Silo Pharma (SILO)?

The current stock price of Silo Pharma (SILO) is $1.15 as of November 14, 2024.

What is the market cap of Silo Pharma (SILO)?

The market cap of Silo Pharma (SILO) is approximately 4.8M.

What does Silo Pharma, Inc. specialize in?

Silo Pharma specializes in developing novel therapeutics that combine traditional and psychedelic treatments for conditions such as PTSD, fibromyalgia, Alzheimer's disease, and other neurological disorders.

What are Silo Pharma's leading development programs?

Silo's leading programs include SPC-15, an intranasal treatment for PTSD; SP-26, a ketamine-loaded implant for chronic pain; and SPC-14, an intranasal compound for Alzheimer's disease.

Who are Silo Pharma's research partners?

Silo Pharma collaborates with Columbia University and the University of Maryland, Baltimore for its research and development programs.

What recent achievements has Silo Pharma announced?

Recent achievements include the provisional patent filing for SP-26 and the exclusive licensing of SPC-15 from Columbia University.

How does Silo Pharma aim to impact the healthcare industry?

Silo aims to revolutionize the healthcare industry by developing transformative treatments for underserved conditions, merging traditional and psychedelic therapies.

Where can I find more information about Silo Pharma?

You can find more information on their official website at www.silopharma.com and on their social media pages on LinkedIn, X, and Facebook.

What is the significance of Silo Pharma's SP-26 program?

SP-26 is significant as it is a ketamine-loaded implant designed to provide time-release pain relief for conditions like fibromyalgia, potentially being the first at-home approved ketamine-based therapeutic.

What progress has been made with the SPC-15 program?

SPC-15 has shown promising preclinical results for PTSD and anxiety, with the company preparing to submit a pre-IND application to the FDA.

What conditions does Silo Pharma aim to address with its treatments?

Silo aims to address conditions including PTSD, fibromyalgia, Alzheimer's disease, Parkinson's disease, and other rare neurological disorders.

How does Silo Pharma fund its research projects?

Silo Pharma provides the necessary financial resources in collaboration with leading medical universities to advance their research from the clinical stage to commercialization.

Silo Pharma, Inc.

Nasdaq:SILO

SILO Rankings

SILO Stock Data

4.80M
4.48M
4.14%
2.13%
2.88%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SARASOTA